Aim: Prostate cancer (PCa) is one of the most common cancer among men in
the world. Prostate specific antigen is the most used biomarker for PCa
diagnosis. In this study we aimed to measure the procalcitonin(PCT) and
C-reactive protein (CRP) levels in patients with PCa. Methods: The
patients who underwent transrectal prostate biopsy and transurethral
prostate surgery in the last 4 years were included in the study. The
patients were divided into two groups according to the pathology
reports, group1; benign prostate hyperplasia and group2; prostate
cancer. MedCalc Statistical Software version 17.6 was used for
statistical analyses. Results: The current study includes 149 patients.
There were 118 patients in group1 and 31 patients in group 2. The mean
age of the patients was 66.85 and 69.41 years in groups respectively.
Serum CRP and PCT levels was 3.33 and 0.01 in group 4.07 and 0.04 in
group 2. Serum PCT levels was significantly higher in patients with PCa.
Conclusion: We found that elevated procalcitonin levels was associated
with prostate cancer. Further studies are needed to define the
relationship between procalcitonin and prostate cancer. What’s Known:
Prostate cancer is the second most common cancer among elderly men.
Prostate specific antigen testisng is usually used in screening and
diagnosis. Unfortunately PSA is not cancer specific and new biomarkers
are needed for prostate cancer management. What’s New: Procalcitonin is
a precursor of calcitonin which is produced by thyroid C-cells and some
neuroendocrine cells. The elevated level of procalcitonin is associated
with bacteremia and sepsis. In this study e investigated the
procalcitonin levels in prostate cancer.